XERS Q4 2020 Earnings — Xeris Biopharma Holdings, Inc. Revenue & Financial Results | Market Cap Arena

XERSXeris Biopharma Holdings, Inc.

$960M

Q4 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$7M+284.8% YoY

Gross Profit

$4M52.5% margin

Operating Income

-$19M-269.7% margin

Net Income

-$22M-304.8% margin

EPS (Diluted)

$-0.41

QoQ Revenue Growth

-24.1%

Cash Flow

Operating Cash Flow

-$11M

Free Cash Flow

-$11M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$159M

Total Liabilities

$125M

Stockholders' Equity

$34M

Cash & Equivalents

$38M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$7M	$2M	+284.8%
Gross Profit	$4M	$261,000	+1342.5%
Operating Income	-$19M	-$33M	+41.0%
Net Income	-$22M	-$33M	+33.9%